Cargando…

Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence

Detalles Bibliográficos
Autor principal:	Bikdeli, Behnood
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543777/ https://www.ncbi.nlm.nih.gov/pubmed/33066998 http://dx.doi.org/10.1016/j.thromres.2020.09.033

Ejemplares similares

To escalate thromboprophylacic heparin intensity in COVID‐19 or not? That is still the question
por: Bikdeli, Behnood
Publicado: (2022)

Thromboprophylaxis strategies to improve the prognosis of COVID-19
por: Bertoletti, Laurent, et al.
Publicado: (2021)

Closer to FREEDOM From Uncertainty
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Omega-3 Supplements and Cardiovascular Diseases
por: Mohebi-Nejad, Azin, et al.
Publicado: (2014)

Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial
por: Rashidi, Farid, et al.
Publicado: (2022)

Cardiac rupture after ST-elevation myocardial infarction (STEMI): a ‘Stitch’ in time?
por: Nagraj, Sanjana, et al.
Publicado: (2022)

Should we prove the balance of baseline data in randomized controlled trials?
por: Kang, Hyun, et al.
Publicado: (2019)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals
por: Talasaz, Azita H., et al.
Publicado: (2022)

Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study
por: Rodríguez, Carmen, et al.
Publicado: (2021)

Randomized Controlled Trials on COVID-19 Should Be Accurate and Trustworthy
por: Mol, Ben W.
Publicado: (2022)

Oral Anticoagulant Therapy: When What Should Not Be Is and What Should Be Is Not
por: Reiffel, James A.
Publicado: (2019)

Haemoperfusion should only be used for COVID-19 in the context of randomized trials
por: Clark, Edward G., et al.
Publicado: (2020)

Response to “Randomized Controlled Trials on COVID-19 Should be Accurate and Trustworthy”
por: Abd-Elsalam, Sherief, et al.
Publicado: (2022)

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19
por: Stone, Gregg W., et al.
Publicado: (2023)

Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
por: Bikdeli, Behnood, et al.
Publicado: (2021)

COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies?
por: Aubignat, M., et al.
Publicado: (2020)

Anticoagulation in COVID-19: It Is Time for High-Quality Evidence
por: Lopes, Renato D., et al.
Publicado: (2020)

Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
por: Thomas, W., et al.
Publicado: (2020)

Age of Data at the Time of Publication of Contemporary Clinical Trials
por: Welsh, John, et al.
Publicado: (2018)

Annual Mortality Related to Pulmonary Embolism in the U.S. Before and During the COVID-19 Pandemic
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

Anticoagulation in COVID-19: reaction to the ACTION trial
por: Berger, Jeffrey S, et al.
Publicado: (2021)

Coagulopathy in COVID-19 and anticoagulation clinical trials
por: Zhang, Heng, et al.
Publicado: (2022)

Should we treat sepsis-induced DIC with anticoagulants?
por: Inata, Yu
Publicado: (2020)

Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial
por: Rodríguez, Carmen, et al.
Publicado: (2022)

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
por: Moodley, Otto, et al.
Publicado: (2015)

Extended anticoagulation after venous thromboembolism: should it be done?
por: Fernandes, Caio J., et al.
Publicado: (2019)

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
por: Talasaz, Azita H., et al.
Publicado: (2021)

Balancing excitation and inhibition in the autistic brain
por: Pretzsch, Charlotte M, et al.
Publicado: (2020)

Keeping Excitation–Inhibition Ratio in Balance
por: Kirischuk, Sergei
Publicado: (2022)

Fungal infections should be part of the core outcome set for COVID-19
por: Verweij, Paul E, et al.
Publicado: (2021)

Anticoagulation for atrial fibrillation in heart failure patients: balancing between Scylla and Charybdis
por: Tsigkas, Grigorios, et al.
Publicado: (2021)

Implementing pharmacist-prescriber collaboration to improve evidence-based anticoagulant use: a randomized trial
por: Smith, Shawna N., et al.
Publicado: (2023)

Anticoagulation in difficult settings RELOADed: Evidence for applicability of direct oral anticoagulants in patients with atrial fibrillation, renal impairment and cancer
por: Fender, Anke C., et al.
Publicado: (2019)

Anticoagulation in COVID-19
por: Atallah, Bassam, et al.
Publicado: (2020)

Anticoagulation in COVID-19
por: Bradbury, Charlotte A, et al.
Publicado: (2022)

The proof for new oral anticoagulants: clinical trial evidence
por: Huisman, Menno V.
Publicado: (2011)

Should we test the prothrombin time in anticoagulated epistaxis patients?
por: Soyka, Michael B., et al.
Publicado: (2013)

Should perioperative anticoagulation be an integral part of the priapism shunting procedure?
por: Lue, Tom F., et al.
Publicado: (2013)

Cerebrovascular Accident due to Thyroid Storm: Should We Anticoagulate?
por: Gonzalez-Bossolo, Alex, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7lvqnhahi1v27pled4la4qv44j